Amsel Medical Raises $7.45M for Revolutionary Surgical Clamping Technology

In a significant step forward for surgical innovation, Amsel Medical is thrilled to announce the successful raising of $7,450,000 in a recent funding round. This significant investment signals strong confidence in Amsel Medical’s vision to revolutionize surgical procedures through its unique mechanical surgical clamping technology. Designed for minimally invasive applications, Amsel Medical delivers its cutting-edge SCureClamp through an 18 G needle, allowing for the precise clamping of blood vessels, ducts, arteries, and veins. This technique mirrors the secure occlusion strength of traditional transfixion sutures but with reduced trauma and recovery time for patients. With the incorporation of iDOT's advanced anchoring feature, the SCureClamp ensures the implant remains firmly in place, effectively eliminating any risk of slippage. The device's innovative design accommodates the occlusion of vessels across various sizes and wall thicknesses, providing surgeons with a versatile tool for complex procedures. The funds raised will primarily be directed towards advancing clinical trials and obtaining regulatory approvals, paving the way for broader market adoption and ultimately transforming how surgeries are performed. Amsel Medical aims to enhance patient outcomes and streamline surgical processes globally, and with the infusion of this funding, the company is excited to expand its operations and accelerate its mission to improve surgical practices for healthcare providers and patients alike.